GlassScriptPhysician profile
Michael W Shen
NPI 1154402238
$14,064.27
in general payments reported to CMS, 2019-2025
66 companies · $4,647 in 2025
The $4,647 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,347 · 2020: $365 · 2021: $455 · 2022: $886 · 2023: $2,657 · 2024: $3,708 · 2025: $4,647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,857.93 |
| Education | $153.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,782.32 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Ucb, INC. | $1,571.76 | 2019-2025 | Rystiggo, Briviact, Nayzilam |
| Neurocrine Biosciences, INC. | $1,015.51 | 2019-2025 | Ingrezza, Ongentys |
| Alexion Pharmaceuticals, INC. | $773.64 | 2019-2025 | Ultomiris, Soliris, Koselugo |
| Eisai INC. | $623.24 | 2019-2025 | |
| Lilly USA, LLC | $614.07 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Argenx US, INC. | $577.33 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Biogen, INC. | $554.77 | 2019-2025 | Vumerity, Tysabri, Qalsody |
| Sk Life Science, INC. | $489.78 | 2021-2025 | Xcopri |
| Pfizer INC. | $465.22 | 2019-2025 | |
| Amgen INC. | $387.17 | 2019-2025 | Uplizna, Aimovig |
| Lundbeck LLC | $364.52 | 2021-2025 | Vyepti, Rexulti |
| Octapharma USA, INC. | $350.35 | 2023-2025 | Octagam Immune Globulin (Human), Panzyga |
| Novartis Pharmaceuticals Corporation | $321.47 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $289.77 | 2022-2024 | Purified Cortrophin Gel |
Show all 65 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Shen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.